Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors
07 Junho 2023 - 8:30AM
Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a
leader in the development of orally delivered peptides and
therapeutic proteins, today announced that it has appointed Haya
Taitel, Head of Sanofi’s Global Transplant Franchise as an
independent director to the Company’s Board of Directors.
"We are thrilled that Haya has joined our
Board," said Miranda Toledano, Chief Executive Officer of Entera.
"With more than 30 years of experience building industry-leading
commercial organizations across big pharma and biotech, Haya brings
a veteran and unique perspective to Entera’s Board of Directors. We
believe that Haya’s track record shepherding late-stage products
through regulatory approval to commercial readiness, implementing
payor and channel strategies for blockbusters, including products
in women’s health, will be invaluable as we continue to prepare our
global strategy related to EB613’s phase 3 program and our future
pipeline. We are humbled that Haya, in addition to our existing
clinical and regulatory advisory board, recognizes the potential
for EB613 and its unique positioning to potentially alter the
paradigm for post-menopausal women with osteoporosis. These
champions are paramount to adequately preparing the success of our
programs.”
"Entera is looking to make a real difference
with its platform technology and core products across major disease
areas with significant unmet need, especially with EB613 for women
at high risk of fracture, there are over 100 million women globally
who could become candidates for this important therapy,” said Haya
Taitel. “I have been following Entera’s regulatory development and
the progress of this program closely and am looking forward to
working with the Board and management team as Entera enters this
pivotal stage for EB613. I am also excited for the pipeline
candidates selected where Entera’s platform appears to provide a
breakthrough simple mini tablet format for patients to better
actively manage their health, such as GLP-2 and PTH for
hypoparathyroidism.”
Ms. Taitel has over 30 years of global C-level
biopharma commercial and strategic executive experience. Ms.
Taitel currently serves as the Head of Sanofi’s Global Transplant
Franchise where she is responsible for increasing franchise growth
and profitability. Prior to her role at Sanofi, Ms. Taitel served
as the Chief Commercial Officer of Kadmon Pharmaceuticals, LLC,
where she contributed to the launch of Rezurock®, from 2013 until
the company was acquired by Sanofi for $1.9 billion in November
2021. Ms. Taitel also led Kadmon Board’s Executive Commercial
Committee. Beginning in 1997, Ms. Taitel had held various
commercial leadership positions of increasing seniority at Johnson
and Johnson in multiple therapeutic areas, including oncology,
immunology, neurology and women’s healthcare. Ms. Taitel holds a
Master of Science, Pharmacology, (PharmD equivalence) from Temple
University and a Bachelor of Science, Pharmacy and Biology from the
Hebrew University School of Pharmacy in Jerusalem, Israel.
About Entera
Entera is a leader in the development of orally
delivered macromolecules, including peptides and other therapeutic
proteins. The Company focuses on significant unmet medical needs
where a daily mini tablet form of a peptide treatment or
replacement therapy holds the potential to transform the standard
of care. The Company’s most advanced product candidates, EB613 for
the treatment of high risk, post-menopausal osteoporosis and EB612
for the treatment of hypoparathyroidism, are in clinical
development. EB613 is the first oral, once daily mini tablet
presentation of synthetic hPTH (1-34), (teriparatide), consisting
of the exact same 34 amino acid sequence as daily subcutaneous
teriparatide injection, Forteo®, which requires daily SC
injections. A placebo controlled, dose ranging Phase 2 study of
EB613 tablets (n= 161) met primary (PD/biomarker) and secondary
endpoints (BMD) in a dose dependent manner and was presented at the
ASBMR 2021 Annual Conference. A phase 1 PK study of novel PTH
formulations is planned for H1 2023 to ascertain feasibility of a
new hypo candidate (a prior formulation had positive Phase 2a data
announced in 2015 and published in JBMR 2019) and for another
potential indication. For more information on Entera Bio, visit
www.enterabio.com.
Cautionary Statement Regarding Forward
Looking Statements
Various statements in this press release are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements (other
than statements of historical facts) in this press release
regarding our prospects, plans, financial position, business
strategy and expected financial and operational results may
constitute forward-looking statements. Words such as, but not
limited to, “anticipate,” “believe,” “can,” “could,” “expect,”
“estimate,” “design,” “goal,” “intend,” “may,” “might,”
“objective,” “plan,” “predict,” “project,” “target,” “likely,”
“should,” “will,” and “would,” or the negative of these terms and
similar expressions or words, identify forward-looking statements.
Forward-looking statements are based upon current expectations that
involve risks, changes in circumstances, assumptions and
uncertainties. Forward-looking statements should not be read as a
guarantee of future performance or results and may not be accurate
indications of when such performance or results will be
achieved.
Important factors that could cause actual
results to differ materially from those reflected in Entera’s
forward-looking statements include, among others: changes in the
interpretation of clinical data; results of our clinical trials;
the FDA’s interpretation and review of our results from and
analysis of our clinical trials; unexpected changes in our ongoing
and planned preclinical development and clinical trials, the timing
of and our ability to make regulatory filings and obtain and
maintain regulatory approvals for our product candidates; the
potential disruption and delay of manufacturing supply chains; loss
of available workforce resources, either by Entera or its
collaboration and laboratory partners; impacts to research and
development or clinical activities that Entera may be contractually
obligated to provide; overall regulatory timelines; the size and
growth of the potential markets for our product candidates; the
scope, progress and costs of developing Entera’s product
candidates; Entera’s reliance on third parties to conduct its
clinical trials; Entera’s expectations regarding licensing,
business transactions and strategic collaborations; Entera’s
operation as a development stage company with limited operating
history; Entera’s ability to continue as a going concern absent
access to sources of liquidity; Entera’s ability to obtain and
maintain regulatory approval for any of its product candidates;
Entera’s ability to comply with Nasdaq’s minimum listing standards
and other matters related to compliance with the requirements of
being a public company in the United States; Entera’s intellectual
property position and its ability to protect its intellectual
property; and other factors that are described in the “Cautionary
Statements Regarding Forward-Looking Statements,” “Risk Factors”
and “Management’s Discussion and Analysis of Financial Condition
and Results of Operations” sections of Entera’s most recent Annual
Report on Form 10-K filed with the SEC, as well as the company’s
subsequently filed Quarterly Reports on Form 10-Q and Current
Reports on Form 8-K. There can be no assurance that the actual
results or developments anticipated by Entera will be realized or,
even if substantially realized, that they will have the expected
consequences to, or effects on, Entera. Therefore, no assurance can
be given that the outcomes stated or implied in such
forward-looking statements and estimates will be achieved. Entera
cautions investors not to rely on the forward-looking statements
Entera makes in this press release. The information in this press
release is provided only as of the date of this press release, and
Entera undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise, except to the extent required by
law.
Contact:
Entera Bio:
Ms. Miranda Toledano
Chief Executive Officer
Entera Bio
Email: miranda@enterabio.com
Entera Bio (NASDAQ:ENTX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Entera Bio (NASDAQ:ENTX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024